AMGN
Amgen Inc.
NASDAQ · USHealthcareDrug Manufacturers - General
$364.17-0.58%
Price as of Jul 20, 2026
AMGN financials
Amgen Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $36.7B | $33.4B | $28.2B | $26.3B |
| Cost of revenue | $10.7B | $12.9B | $8.4B | $6.4B |
| Gross profit | $26.0B | $20.6B | $19.8B | $19.9B |
| Operating expenses | $15.3B | $13.3B | $11.8B | $10.4B |
| Operating income | $10.7B | $7.3B | $7.9B | $9.6B |
| Net income | $7.7B | $4.1B | $6.7B | $6.6B |
| EBITDA | $16.9B | $13.4B | $14.8B | $12.2B |
| Basic EPS | $14.33 | $7.62 | $12.56 | $12.18 |
| Diluted EPS | $14.23 | $7.56 | $12.49 | $12.11 |
| Balance sheet | ||||
| Cash & equivalents | $9.1B | $12.0B | $10.9B | $7.6B |
| Total assets | $90.6B | $91.8B | $97.2B | $65.1B |
| Total liabilities | $81.9B | $86.0B | $90.9B | $61.5B |
| Stockholders’ equity | $8.7B | $5.9B | $6.2B | $3.7B |
| Total debt | $54.6B | $60.1B | $64.6B | $38.9B |
| Net debt | $45.5B | $48.1B | $53.7B | $31.3B |
| Cash flow | ||||
| Operating cash flow | $10.0B | $11.5B | $8.5B | $9.7B |
| Capital expenditure | -$1.9B | -$1.1B | -$1.1B | -$936.0M |
| Free cash flow | $8.1B | $10.4B | $7.4B | $8.8B |
| Dividends paid | -$5.1B | -$4.8B | -$4.6B | -$4.2B |
| Share repurchases | $0.00 | -$200.0M | $0.00 | -$6.4B |